Lilly's halts trials of Zyprexa replacement in schizophrenia
This article was originally published in Scrip
Eli Lilly ceded defeat in its fight to replace some of the revenue lost to generic competition for its blockbuster Zyprexa (olanzapine) when on 29 August it announced it would end development of the schizophrenia drug candidate pomaglumetad methionil (LY2140023) – an oral glutamate 2 and 3 receptor agonist – after a second pivotal study failure.
You may also be interested in...
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.